A Cancer-Specific Monoclonal Antibody against HER2 Exerts Antitumor Activities in Human Breast Cancer Xenograft Models

Mika K. Kaneko,Hiroyuki Suzuki,Tomokazu Ohishi,Takuro Nakamura,Tomohiro Tanaka,Yukinari Kato
DOI: https://doi.org/10.3390/ijms25031941
IF: 5.6
2024-02-06
International Journal of Molecular Sciences
Abstract:Monoclonal antibody (mAb)-based and/or cell-based immunotherapies provide innovative approaches to cancer treatments. However, safety concerns over targeting normal cells expressing reactive antigens still exist. Therefore, the development of cancer-specific mAbs (CasMabs) that recognize cancer-specific antigens with in vivo antitumor efficacy is required to minimize the adverse effects. We previously screened anti-human epidermal growth factor receptor 2 (HER2) mAbs and successfully established a cancer-specific anti-HER2 mAb, H2Mab-250/H2CasMab-2 (IgG1, kappa). In this study, we showed that H2Mab-250 reacted with HER2-positive breast cancer cells but did not show reactivity to normal epithelial cells in flow cytometry. In contrast, a clinically approved anti-HER2 mAb, trastuzumab, recognized both breast cancer and normal epithelial cells. We further compared the affinity, effector activation, and antitumor effect of H2Mab-250 with trastuzumab. The results showed that H2Mab-250 exerted a comparable antitumor effect with trastuzumab in the mouse xenograft models of BT-474 and SK-BR-3, although H2Mab-250 possessed a lower affinity and effector activation than trastuzumab in vitro. H2Mab-250 could contribute to the development of chimeric antigen receptor-T or antibody–drug conjugates without adverse effects for breast cancer therapy.
biochemistry & molecular biology,chemistry, multidisciplinary
What problem does this paper attempt to address?
The problem this paper attempts to address is the development of a cancer-specific monoclonal antibody (CasMab) to reduce the adverse effects on normal cells associated with traditional anti-HER2 monoclonal antibodies (such as trastuzumab) in the treatment of HER2-positive breast cancer. Specifically, the researchers aim to develop a monoclonal antibody that can specifically recognize HER2-positive breast cancer cells without reacting with normal epithelial cells, thereby improving the safety and efficacy of the treatment. ### Main Research Background and Issues 1. **Role of HER2 in Breast Cancer**: - HER2 (Human Epidermal Growth Factor Receptor 2) is overexpressed in approximately 20% of breast cancers, which typically have higher recurrence rates and shorter overall survival. - HER2 overexpression leads to the activation of downstream signaling pathways, promoting cancer cell proliferation, survival, and invasiveness. 2. **Limitations of Existing Treatments**: - Trastuzumab is a clinically approved anti-HER2 monoclonal antibody that shows significant antitumor effects. - However, trastuzumab reacts not only with HER2-positive breast cancer cells but also with normal epithelial cells, leading to adverse effects such as cardiotoxicity. 3. **Research Objectives**: - Develop a cancer-specific anti-HER2 monoclonal antibody (H2Mab-250) that can specifically recognize HER2-positive breast cancer cells without reacting with normal epithelial cells. - Compare the differences between H2Mab-250 and trastuzumab in terms of affinity, effector cell activation, and antitumor effects, and evaluate its therapeutic potential in mouse xenograft models. ### Research Methods and Results 1. **Antibody Screening and Identification**: - Researchers successfully developed H2Mab-250 by screening anti-HER2 monoclonal antibodies, which reacted only with HER2-positive breast cancer cells in flow cytometry and not with normal epithelial cells. 2. **Affinity and Effector Cell Activation**: - Through ELISA experiments, researchers found that the affinity of H2Mab-250 was slightly lower than that of trastuzumab. - In ADCC reporter gene assays, the effector cell activation ability of H2Mab-250 was also lower than that of trastuzumab. 3. **Immunohistochemical Analysis**: - H2Mab-250 exhibited excellent reactivity in HER2-positive breast cancer tissues and no reactivity in normal tissues. 4. **In Vivo Antitumor Effects**: - In BT-474 and SK-BR-3 xenograft models, both H2Mab-250 and trastuzumab significantly reduced tumor volume, with H2Mab-250 showing antitumor effects comparable to trastuzumab. ### Conclusion This study successfully developed a cancer-specific anti-HER2 monoclonal antibody, H2Mab-250, which demonstrated good antitumor effects in both in vitro and in vivo experiments, with fewer adverse reactions to normal cells. This finding provides new insights for developing safer and more effective breast cancer treatments.